📊 BEAM Key Takeaways
Investment Thesis
Beam Therapeutics demonstrates strong revenue growth of 120% YoY, indicating successful commercialization efforts, but faces severe profitability challenges with negative operating margins of -274.6% and substantial operating cash burn of -345.1M annually. The company's high liquidity position provides runway, but the trajectory of losses relative to revenue growth raises concerns about the path to profitability and capital efficiency.
BEAM Strengths
- Strong revenue growth of 120% YoY demonstrates market traction and successful product commercialization
- Excellent liquidity position with current ratio of 13.09x and $294.9M in cash providing substantial operational runway
- Minimal debt burden with 0.00x debt-to-equity ratio limits financial distress risk
BEAM Risks
- Severe operating losses of -$383.7M against $139.7M revenue indicates fundamental unprofitability and massive cash burn
- Operating cash flow of -$345.1M annually combined with negative free cash flow of -$360.0M suggests unsustainable cash consumption rate
- Operating margin of -274.6% and net margin of -57.2% indicate the company is burning significant capital per dollar of revenue with no clear near-term path to profitability
Key Metrics to Watch
- Operating cash flow trajectory and burn rate relative to revenue growth
- Path to operating profitability and timeline for achieving positive operating margins
- Cash runway and rate of cash depletion given current burn levels
BEAM Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 13.09x current ratio provides a solid financial cushion.
BEAM Profitability Ratios
BEAM vs Healthcare Sector
How Beam Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BEAM Balance Sheet & Liquidity
BEAM 5-Year Financial Trend
5-Year Trend Summary: Beam Therapeutics Inc.'s revenue has grown significantly by 629% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.72 indicates the company is currently unprofitable.
BEAM Growth Metrics (YoY)
BEAM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9.7M | -$91.1M | $-1.10 |
| Q2 2025 | $8.5M | -$91.1M | $-1.00 |
| Q1 2025 | $7.4M | -$98.7M | $-1.21 |
| Q3 2024 | $14.3M | -$82.8M | $-1.17 |
| Q2 2024 | $11.8M | -$82.8M | $-1.08 |
| Q1 2024 | $7.4M | -$96.5M | $-1.21 |
| Q3 2023 | $15.8M | -$69.2M | $-1.22 |
| Q2 2023 | $16.7M | -$69.2M | $-1.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BEAM Capital Allocation
BEAM SEC Filings
Access official SEC EDGAR filings for Beam Therapeutics Inc. (CIK: 0001745999)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BEAM
What is the AI rating for BEAM?
Beam Therapeutics Inc. (BEAM) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BEAM's key strengths?
Strong revenue growth of 120% YoY demonstrates market traction and successful product commercialization. Excellent liquidity position with current ratio of 13.09x and $294.9M in cash providing substantial operational runway.
What are the risks of investing in BEAM?
Severe operating losses of -$383.7M against $139.7M revenue indicates fundamental unprofitability and massive cash burn. Operating cash flow of -$345.1M annually combined with negative free cash flow of -$360.0M suggests unsustainable cash consumption rate.
What is BEAM's revenue and growth?
Beam Therapeutics Inc. reported revenue of $139.7M.
Does BEAM pay dividends?
Beam Therapeutics Inc. does not currently pay dividends.
Where can I find BEAM SEC filings?
Official SEC filings for Beam Therapeutics Inc. (CIK: 0001745999) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BEAM's EPS?
Beam Therapeutics Inc. has a diluted EPS of $-0.81.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.